ImClone Systems Company Information

The Science Employer Guide contains these additional fields as well as 98 pages of hand approved profiles. Learn more here.

Profile:

ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company (NYSE:LLY), is committed to advancing oncology care by developing a portfolio of targeted biologic treatments designed to address the medical needs of patients with a variety of cancers. Founded in 1984, ImClone has a rich culture of discovery and deep expertise in oncology. Beyond its marketed product ERBITUX®, ImClone has several additional investigational monoclonal antibodies in various stages of clinical development. ImClone's research and clinical development capabilities are augmented by its expertise in the scale-up and manufacturing of biologics. The company's state-of-the-art FDA-approved manufacturing facilities provide it with one of the largest biologic manufacturing capacities in the world.